Loading, Please Wait...
PHOENIX, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp market. Founder and Chairman, Todd Denkin, joined Stock Day host Everett Jolly to discuss their advanced testing and analysis services, as well as the Company’s launch of GroSciences.
Jolly began the interview by commenting on the Company’s steady increase in revenue and asked Denkin to explain how Digipath, Inc. has achieved this. Denkin explained that the revenue increases all revolve around Nevada and its growth in cannabis industry, which is rapidly developing. “As the market place grows, we will grow along with it,” stated Denkin.
Jolly then inquired about CBD testing and how it is performed throughout the industry. Denkin explained that currently there is no regulation that takes place for strain names, in fact many are essentially fabricated. This makes it difficult to offer consumers a standard and officially identified product. However, this is where genotype testing comes into play, which has the ability to verify the desired profiling. This pharmaceutical-grade analysis and testing is a key service that the Company offers to producers and consumers in an effort to maximize the quality of their clients’ cannabinoid products.
Denkin then brought listeners up-to-speed on the Company’s recent launch of their subsidiary, GroSciences. He shared that GroSciences was created based on their extensive collection of data to develop and license specific formulations to other producers and product makers in the industry.
Jolly then asked about the Company’s international growth and their plan going forward. Denkin shared that international exporting is the next big step in the cannabis market, and their sights are set to Columbia due to its encouragement of the cannabis industry. Denkin shared that both exports and imports will have to be tested, placing Digipath, Inc. in a beneficial position to utilize their testing and analysis services.
Denkin closed by sharing his excitement for the Company’s plan to expand into hemp-friendly areas where related products are also required to go through a rigorous testing process, as this will be another steady source of revenue for Digipath, Inc.
To hear the entire interview with Todd Denkin, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-todd-denkin-of-digipath-inc-otcqb-digp-3/
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Digipath Investor Relations & Financial Media
Toll Free: (888) 216-3595
Information About Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.